golimumab (100 mg) every 4 weeks, with or without methotrexate (MTX) and 50 mg golimumab plus MTX	baseline	Disease Activity Score 28 joints C-reactive protein (DAS28-CRP) and simplified disease activity index (SDAI) score	1147	1410	Most patients received combined 50 mg golimumab plus MTX (41/43). In these patients, the primary endpoint, clinical remission, was attained in 83 % of patients according to DAS28-CRP criteria (p < 0.001) and 69 % according to SDAI criteria (p < 0.001) by week 24.
golimumab (100 mg) every 4 weeks, with or without methotrexate (MTX) and 50 mg golimumab plus MTX	baseline	Disease Activity Score 28 joints C-reactive protein (DAS28-CRP) and simplified disease activity index (SDAI) score	-1	-1	The mean DAS28-CRP 4 weeks after the start of treatment was significantly improved compared with the pretreatment score [mean DAS28-CRP at week 4 = 1.80 vs 4.14 (range 1.28â€“7.04) at baseline; p < 0.001].
